Company intelligence / Profile preview
Targazyme
Carlsbad/San Diego, California, United Statestargazyme.com ↗
- Ownership
- Private
- Employees
- ~11
- Development stage
- Phase 3
01
Overview
Dual mechanism: Enhanced immune cell delivery + amplified anti-tumor activity. Aims to replace chemotherapy/radiation/surgery in some cases. Focus on reducing treatment side effects.
- Therapeutic areas
- OncologyImmunology
- Modalities
- Enzyme-based biologicsCell therapies(Off-the-shelf) T-cell products
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
03
Partnerships
Kyowa Hakko KirinFlorida BiologixMD Anderson Cancer CenterOklahoma Medical Research FoundationFred Hutchinson Cancer Research CenterUCLA Medical CenterStanford University Medical Center
Beyond the preview
Go deeper on Targazyme.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Targazyme.